Novo Nordisk's Q2 2025 sales surge as Wegovy demand grows, driven by new obesity drug data. Click here to read an analysis of ...

If you knew a medicine wasn’t regulated or reviewed by the U.S. Food and Drug Administration, would you still be willing to take it? My guess is that most people wouldn’t willingly put an unknown ...

Fractyl Health said its experimental outpatient procedure helped preserve weight loss after discontinuation of a GLP-1 drug, sending the company's shares 23% higher in premarket trading on Friday.

These stocks come with some uncertainty, but they have strong fundamentals and trade at low earnings multiples.

Eli Lilly's GLP-1 Pill Just Beat Out Novo Nordisk's in a Test. Here's 1 Thing Investors Need to Know. The secondary endpoints included weight loss, and, here again, orforglipron demonstrated ...

Looking ahead to 2026, new opportunities in private label and contract manufacturing are on the rise. Discover the key trends ...

A new daily pill may help people with obesity lose a significant amount of weight without the need for injections. The ...

Serena Williams’ candid reaction to a cotton display went viral, dividing fans and fueling a fiery online discussion.

Recently, a different weight loss drug, ecnoglutide, with an active ingredient of the peptide ecnoglutide, has been utilized ...

Medicare Part D coverage of glucagon-like peptide-1 receptor agonists— widely prescribed for diabetes and increasingly sought for obesity and related conditions— has remained broad. A research letter ...

The Scan by 2 Minute Medicine® is a pop-culture medical newsletter and exclusive benefit for 2 Minute Medicine Plus ...

A new oral weight loss medication, orforglipron, demonstrated meaningful weight loss results in phase 3 trials, potentially ...